Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
Key Highlights
- ➤Autolus will release Q3 2026 financial results before U.S. markets open November 10, 2026
- ➤Management will host an 8:30am EST conference call and webcast
- ➤Autolus has a marketed therapy and pipeline candidates targeting cancer and autoimmune disease
LONDON and GAITHERSBURG, Md., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its third quarter 2026 financial results and operational highlights before open of U.S. markets on Tuesday, November 10, 2026.
Management will host a conference call and webcast at 8:30am EST / 1:30pm GMT to discuss the Company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
Get started
Create a free account to read the full story.